Aurinia Pharmaceuticals Inc.
HealthcareNASDAQ:AUPH · NASDAQ Global Market
-$0.03 today
Vol 0.67M · Avg 1.28M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
49.4%
avg -31.5%
ROIC
15.5%
avg -28.3%
ROA
38.2%
avg -23.5%
Analysis
ROE is currently the strongest return metric at 49.4% versus its period average of -31.5%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Peter S. Greenleaf | Consultant | $1.70M | — | 56 | $1.84M | 1.43% |
Stephen Robertson | Chief Legal Officer, Corporate Secretary & Chief Compliance Officer | $923,480.00 | — | 44 | $621,402.00 | 0.48% |
Michael S. Hearne | Chief Financial Officer | $866,870.00 | — | 63 | $70,230.00 | 0.05% |
Gregory F. Keenan | Senior VP & Chief Medical Officer | $779,114.00 | — | 64 | $154,449.00 | 0.12% |
Kevin C. Tang | Chairman & CEO | — | — | 59 | $10,000.00 | <0.01% |
Michael Gammons | Vice President & Chief Information Officer | — | — | — | $70,230.00 | 0.05% |
Stewart Kroll | Chief Development Officer | — | — | 67 | — | — |
Thomas Wei | Chief Scientific Officer | — | — | 50 | — | — |
Andrea Levin Christopher | Executive Director of Corporate Communications & Investor Relations | — | — | — | — | — |
Ryan Cole | Chief Operating Officer | — | — | 39 | $116,144.00 | 0.09% |
Richard Lewis | Vice President of Sales | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
14
$38.73M
Sells
1
$210,000.00
Net Sentiment
+$38.52M
Net buying
Most Active
TANG KEVIN
14 transactions
1–10 of 15
Analysis
Insiders reported 14 buys worth $38.73M and 1 sells worth $210,000.00 over the last 12 months. That adds up to net buying of $38.52M. TANG KEVIN was the most active insider with 14 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | -66.3% | +67.8% (15yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at -66.3% over three years. Forward estimates point to Revenue at +67.8% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Vera Therapeutics, Inc.
NASDAQ:VERA
$2.46B
Celldex Therapeutics, Inc.
NASDAQ:CLDX
$2.08B
Harmony Biosciences Holdings, Inc.
NASDAQ:HRMY
$1.99B
Stoke Therapeutics, Inc.
NASDAQ:STOK
$1.86B
Nuvation Bio Inc.
NYSE:NUVB
$1.71B
AbCellera Biologics Inc.
NASDAQ:ABCL
$1.60B
Immunocore Holdings plc
NASDAQ:IMCR
$1.47B
Biohaven Ltd.
NYSE:BHVN
$1.19B
MannKind Corporation
NASDAQ:MNKD
$1.13B
Janux Therapeutics, Inc.
NASDAQ:JANX
$826.95M
Who manages AUPH?
Aurinia Pharmaceuticals Inc. (AUPH) lists 11 active executives. The top listed executive is Stephen Robertson, Chief Legal Officer, Corporate Secretary & Chief Compliance Officer.
Are AUPH insiders buying or selling?
Recent insider activity shows net buying of $69.49M.
Explore More
Continue the stock analysis
Jump to another research area for this company.